Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: SPERO THERAPEUTICS, INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2015-06-30 to 2021-06-15
Current total value of award: $5923718.98
Description: DEVELOPMENT OF A SECOND GENERATION POLYMYXIN FOR THERAPY OF MDR GRAM-NEGATIVE INFECTIONS